

Helio Tedesco-Silva Junior

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7131503/publications.pdf>

Version: 2024-02-01

123
papers

4,821
citations

201674

27
h-index

102487

66
g-index

125
all docs

125
docs citations

125
times ranked

4379
citing authors

#	ARTICLE	IF	CITATIONS
1	Migratory pattern of the coronavirus disease 2019 and high fatality rates among kidney transplant recipients: report from the Brazilian Multicenter Cohort Study. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2022, 44, 428-433.	0.9	5
2	Development and validation of a simple web-based tool for early prediction of COVID-19-associated death in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 610-625.	4.7	16
3	Efficacy of Convalescent Plasma to Treat Mild to Moderate COVID-19 in Kidney Transplant Patients: A Propensity Score Matching Analysis. <i>Transplantation</i> , 2022, 106, e92-e94.	1.0	21
4	High soluble HLA-DQB2 levels in posttransplant serum are associated with kidney graft dysfunction. <i>International Journal of Immunogenetics</i> , 2022, , .	1.8	1
5	Predictive ability of severity scores and outcomes for mortality in kidney transplant recipients with coronavirus disease 2019 admitted to the intensive care unit: results from a Brazilian single-center cohort study. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> . 2022. 44. 383-394.	0.9	2
6	Long-term clinical outcomes of patients with nonsignificant transplanted renal artery stenosis. <i>BMC Nephrology</i> , 2022, 23, 61.	1.8	1
7	The Higher COVID-19 Fatality Rate Among Kidney Transplant Recipients Calls for Further Action. <i>Transplantation</i> , 2022, 106, 908-910.	1.0	15
8	Inactivated Whole-virus Vaccine Triggers Low Response Against SARS-CoV-2 Infection Among Renal Transplant Patients: Prospective Phase 4 Study Results. <i>Transplantation</i> , 2022, 106, 853-861.	1.0	13
9	Critically important outcomes for infection in trials in kidney transplantation: An international survey of patients, caregivers, and health professionals. <i>Clinical Transplantation</i> , 2022, 36, e14660.	1.6	2
10	Immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated CoronaVac vaccine among patients on dialysis: phase 4 study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 816-817.	2.9	2
11	Evaluation of psychological symptoms in patients before and after simultaneous pancreas-kidney transplantation: a single-center cross-sectional study. <i>Acta Cirurgica Brasileira</i> , 2022, 37, e370202.	0.7	1
12	Demonstrating Benefit-Risk Profiles of Novel Therapeutic Strategies in Kidney Transplantation: Opportunities and Challenges of Real-World Evidence. <i>Transplant International</i> , 2022, 35, 10329.	1.6	5
13	The Mycophenolate-based Immunosuppressive Regimen Is Associated With Increased Mortality in Kidney Transplant Patients With COVID-19. <i>Transplantation</i> , 2022, 106, e441-e451.	1.0	4
14	Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal. <i>American Journal of Transplantation</i> , 2021, 21, 123-137.	4.7	12
15	Acute rejection in pediatric renal transplantation: Retrospective study of epidemiology, risk factors, and impact on renal function. <i>Pediatric Transplantation</i> , 2021, 25, e13856.	1.0	3
16	Decreased incidence of acute rejection without increased incidence of cytomegalovirus (CMV) infection in kidney transplant recipients receiving rabbit anti-thymocyte globulin without CMV prophylaxis â€” a cohort single-center study. <i>Transplant International</i> , 2021, 34, 339-352.	1.6	6
17	Kidney Transplantation in Patients With SARS-CoV-2 Infection: A Case Series Report. <i>Transplantation</i> , 2021, 105, e1-e3.	1.0	8
18	Long-term Efficacy and Safety of Everolimus Versus Mycophenolate in Kidney Transplant Recipients Receiving Tacrolimus. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	1.0	3

#	ARTICLE	IF	CITATIONS
19	Range and Consistency of Infection Outcomes Reported in Trials Conducted in Kidney Transplant Recipients: A Systematic Review. <i>Transplantation</i> , 2021, 105, 2632-2638.	1.0	4
20	The Full Spectrum of COVID-19 Development and Recovery Among Kidney Transplant Recipients. <i>Transplantation</i> , 2021, 105, 1433-1444.	1.0	30
21	Kidney transplantation in the time of COVID-19: Dilemmas, experiences, and perspectives. <i>Transplant Infectious Disease</i> , 2021, 23, e13600.	1.7	7
22	Exploring the causes of the high incidence of delayed graft function after kidney transplantation in Brazil: a multicenter study. <i>Transplant International</i> , 2021, 34, 1093-1104.	1.6	15
23	The influence of the antithymocyte globulin dose on clinical outcomes of patients undergoing kidney retransplantation. <i>PLoS ONE</i> , 2021, 16, e0251384.	2.5	4
24	Presumed cytomegalovirus retinitis late after kidney transplant. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2021, , .	0.9	4
25	<scp>HLA</scp> homozygosity is associated with susceptibility to <scp>COVID</scp>. <i>Hla</i> , 2021, 98, 122-131.	0.6	14
26	High mortality among kidney transplant recipients diagnosed with coronavirus disease 2019: Results from the Brazilian multicenter cohort study. <i>PLoS ONE</i> , 2021, 16, e0254822.	2.5	51
27	Clinical impact, reactogenicity, and immunogenicity after the first CoronaVac dose in dialysis patients: a phase IV prospective study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2612-2615.	2.9	3
28	Recurrence of IgA Nephropathy after Kidney Transplantation in Adults. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1247-1255.	4.5	35
29	Lower seroprevalence for SARS-CoV-2-specific antibodies among kidney transplant recipients compared to the general population in the city of Sao Paulo, Brazil. <i>Transplant Infectious Disease</i> , 2021, 23, e13706.	1.7	5
30	Cholecystectomy-Associated Complications in Kidney Transplant Recipients Compared With the General Population. <i>Transplantation Proceedings</i> , 2021, 53, 2291-2297.	0.6	0
31	Improving data quality in liquid chromatography-mass spectrometry metabolomics of human urine. <i>Journal of Chromatography A</i> , 2021, 1654, 462457.	3.7	1
32	An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients. <i>Transplantation Reviews</i> , 2021, 36, 100655.	2.9	15
33	COVID-19 pandemic and worldwide organ transplantation: a population-based study. <i>Lancet Public Health</i> , The, 2021, 6, e709-e719.	10.0	139
34	Challenges of Multidrug-resistant New Delhi Metallo-beta-Lactamase (NDM-1)-producing Enterobacteriaceae in Kidney Transplant Patients. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2021, , .	0.9	2
35	Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study. <i>BMJ Open</i> , 2021, 11, e052138.	1.9	24
36	Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study. <i>The Lancet Digital Health</i> , 2021, 3, e795-e805.	12.3	25

#	ARTICLE	IF	CITATIONS
37	Is There Sufficient Evidence Justifying Limited Access of Jehovahâ€™s Witness Patients to Kidney Transplantation?. <i>Transplantation</i> , 2021, 105, 249-254.	1.0	1
38	<i>CYP3A5</i> and <i>CYP2C8</i> variants influence exposure and clinical outcomes of tacrolimus-based therapy. <i>Pharmacogenomics</i> , 2020, 21, 7-21.	1.3	12
39	Budd-Chiari Syndrome after Bilateral Nephrectomy for Polycystic Kidney Disease in a Kidney Transplant Recipient. <i>Urologia Internationalis</i> , 2020, 104, 330-332.	1.3	0
40	Can Mammalian Target of Rapamycin Inhibitors Replace Mycophenolate in Hypersensitized Kidney Transplant Recipients?. <i>Transplantation</i> , 2020, 104, 1535-1536.	1.0	0
41	The Influence of Antithymocyte Globulin Dose on the Incidence of CMV Infection in High-risk Kidney Transplant Recipients Without Pharmacological Prophylaxis. <i>Transplantation</i> , 2020, 104, 2139-2147.	1.0	12
42	Differentially expressed urinary exo-miRs and clinical outcomes in kidney recipients on short-term tacrolimus therapy: a pilot study. <i>Epigenomics</i> , 2020, 12, 2019-2034.	2.1	13
43	Differential expression of genes related to calcineurin and mTOR signaling and regulatory miRNAs in peripheral blood from kidney recipients under tacrolimus-based therapy. <i>Annals of Translational Medicine</i> , 2020, 8, 1051-1051.	1.7	3
44	Impact of Combinations of Donor and Recipient Ages and Other Factors on Kidney Graft Outcomes. <i>Frontiers in Immunology</i> , 2020, 11, 954.	4.8	11
45	Recycling of predictors used to estimate glomerular filtration rate: Insight into lateral collinearity. <i>PLoS ONE</i> , 2020, 15, e0228842.	2.5	1
46	Brasil: the leading public kidney transplant program worldwide. <i>Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira</i> , 2020, 66, 708-709.	0.7	6
47	Early Hospital Readmission (EHR) in kidney transplantation: a review article. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2020, 42, 231-237.	0.9	6
48	Recurrence of FSGS after Kidney Transplantation in Adults. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 247-256.	4.5	94
49	Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 811-820.	2.0	5
50	Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial. <i>American Journal of Transplantation</i> , 2019, 19, 811-822.	4.7	18
51	Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment. <i>Clinical Transplantation</i> , 2019, 33, e13689.	1.6	5
52	Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor. <i>Transplant International</i> , 2019, 32, 1127-1143.	1.6	15
53	Kidney Allocation System for Transplantation in Brazil. <i>Current Transplantation Reports</i> , 2019, 6, 209-213.	2.0	3
54	Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. <i>Transplantation Reviews</i> , 2019, 33, 191-199.	2.9	12

#	ARTICLE	IF	CITATIONS
55	Chikungunya in a kidney transplant recipient: a case report. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2019, 41, 575-579.	0.9	5
56	ATHENA: wisdom and warfare in defining the role of de novo mTOR inhibition in kidney transplantation. <i>Kidney International</i> , 2019, 96, 27-30.	5.2	6
57	The Challenges Associated With a Calcineurin Inhibitor-free Regimen After Heart Transplantation. <i>Transplantation</i> , 2019, 103, 664-665.	1.0	0
58	Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. <i>American Journal of Transplantation</i> , 2019, 19, 3018-3034.	4.7	97
59	Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy. <i>Transplant Infectious Disease</i> , 2019, 21, e13106.	1.7	10
60	Clinical features and outcomes of kidney transplant recipients with focal segmental glomerulosclerosis recurrence. <i>Nephrology</i> , 2019, 24, 1179-1188.	1.6	4
61	Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study. <i>Transplantation</i> , 2019, 103, 1953-1963.	1.0	69
62	Chronic kidney disease progression in kidney transplant recipients: A focus on traditional risk factors. <i>Nephrology</i> , 2019, 24, 141-147.	1.6	22
63	Early hospital readmission after kidney transplantation under a public health care system. <i>Clinical Transplantation</i> , 2019, 33, e13467.	1.6	13
64	Influence of epidemiology, immunosuppressive regimens, clinical presentation, and treatment on kidney transplant outcomes of patients diagnosed with tuberculosis: A retrospective cohort analysis. <i>American Journal of Transplantation</i> , 2019, 19, 1421-1431.	4.7	22
65	The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive recipient negative (D+/R~) kidney transplant recipients. <i>Transplant Infectious Disease</i> , 2018, 20, e12907.	1.7	10
66	Influence of immunosuppressive drugs on the CD30 molecule in kidney transplanted patients. <i>Human Immunology</i> , 2018, 79, 550-557.	2.4	2
67	Sexual acquisition of HIV infection after solid organ transplantation: Late presentation and potentially fatal complications. <i>Transplant Infectious Disease</i> , 2018, 20, e12894.	1.7	5
68	Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 52-58.	2.0	3
69	Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial. <i>Transplantation Direct</i> , 2018, 4, e380.	1.6	19
70	Optimizing the Clinical Utility of Sirolimus-Based Immunosuppression for Kidney Transplantation. <i>Clinical Transplantation</i> , 2018, 33, e13464.	1.6	12
71	Polymorphisms in mTOR and Calcineurin Signaling Pathways Are Associated With Long-Term Clinical Outcomes in Kidney Transplant Recipients. <i>Frontiers in Pharmacology</i> , 2018, 9, 1296.	3.5	7
72	Tolerability of mycophenolate sodium in renal transplant recipients. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 1548-1558.	2.1	4

#	ARTICLE	IF	CITATIONS
73	Sepsis-like histoplasmosis in a kidney transplant patient. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2018, 40, 95-97.	0.9	4
74	A large, international study on post-transplant glomerular diseases: the TANGO project. <i>BMC Nephrology</i> , 2018, 19, 229.	1.8	21
75	The effect of anti- θ lymphocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis. <i>Transplant Infectious Disease</i> , 2018, 20, e12919.	1.7	7
76	Heightened expression of HLA-DQB1 and HLA-DQB2 in pre-implantation biopsies predicts poor late kidney graft function. <i>Human Immunology</i> , 2018, 79, 594-601.	2.4	12
77	Genetic diversity of <i>Pneumocystis jirovecii</i> from a cluster of cases of pneumonia in renal transplant patients: Cross-sectional study. <i>Mycoses</i> , 2018, 61, 845-852.	4.0	9
78	Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1979-1991.	6.1	193
79	Infectious complications as the leading cause of death after kidney transplantation: analysis of more than 10,000 transplants from a single center. <i>Journal of Nephrology</i> , 2017, 30, 601-606.	2.0	35
80	Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3-year retrospective cohort study. <i>Transplant Infectious Disease</i> , 2017, 19, e12724.	1.7	3
81	Randomized Trial of Machine Perfusion Versus Cold Storage in Recipients of Deceased Donor Kidney Transplants With High Incidence of Delayed Graft Function. <i>Transplantation Direct</i> , 2017, 3, e155.	1.6	41
82	Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus. <i>American Journal of Nephrology</i> , 2017, 45, 497-508.	3.1	15
83	Influence of $ABCC2$, $CYP2C8$, and $CYP2J2$ Polymorphisms on Tacrolimus and Mycophenolate Sodium-Based Treatment in Brazilian Kidney Transplant Recipients. <i>Pharmacotherapy</i> , 2017, 37, 535-545.	2.6	31
84	Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus. <i>Transplantation</i> , 2017, 101, 844-850.	1.0	30
85	Efficacy of Prolonged- and Immediate-release Tacrolimus in Kidney Transplantation: A Pooled Analysis of Two Large, Randomized, Controlled Trials. <i>Transplantation Proceedings</i> , 2017, 49, 2040-2049.	0.6	10
86	Cost-Effectiveness Analysis of Everolimus versus Mycophenolate in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis for Cytomegalovirus Infection: A Short-Term Pharmacoeconomic Evaluation (12 Months). <i>Value in Health Regional Issues</i> , 2017, 14, 108-115.	1.2	6
87	Long-Term Follow-Up of De Novo Use of mTOR and Calcineurin Inhibitors After Kidney Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 22-31.	2.0	17
88	Plasma proteomics for the assessment of acute renal transplant rejection. <i>Life Sciences</i> , 2016, 158, 111-120.	4.3	13
89	Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens. <i>Pharmacotherapy</i> , 2016, 36, 152-165.	2.6	9
90	Targeted preemptive therapy according to perceived risk of CMV infection after kidney transplantation. <i>Brazilian Journal of Infectious Diseases</i> , 2016, 20, 576-584.	0.6	14

#	ARTICLE	IF	CITATIONS
91	Renal transplantation in human immunodeficiency virus-infected recipients: a case-control study from the Brazilian experience. <i>Transplant Infectious Disease</i> , 2016, 18, 730-740.	1.7	6
92	Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 462-472.	1.5	33
93	Predicting delayed kidney graft function with gene expression in preimplantation biopsies and first-day posttransplant blood. <i>Human Immunology</i> , 2016, 77, 353-357.	2.4	2
94	De novo everolimus for recipients of kidney transplants from HLA identical donors. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2016, 38, 225-33.	0.9	2
95	Reviewing 15 years of experience with sirolimus. <i>Transplantation Research</i> , 2015, 4, 5-11.	1.5	8
96	Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. <i>American Journal of Transplantation</i> , 2015, 15, 2655-2664.	4.7	120
97	Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus. <i>Transplantation</i> , 2015, 99, 2372-2381.	1.0	24
98	Post-transplant soluble CD30 levels are associated with early subclinical rejection in kidney transplantation. <i>Transplant Immunology</i> , 2015, 32, 61-65.	1.2	21
99	Prolonged Delayed Graft Function Is Associated with Inferior Patient and Kidney Allograft Survivals. <i>PLoS ONE</i> , 2015, 10, e0144188.	2.5	61
100	TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation. <i>Open Access Journal of Clinical Trials</i> , 2014, , 45.	1.5	19
101	Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. <i>BMJ, The</i> , 2014, 349, g6679-g6679.	6.0	252
102	Outcomes in Obese Kidney Transplant Recipients. <i>Transplantation Proceedings</i> , 2014, 46, 3416-3419.	0.6	21
103	Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens. <i>International Urology and Nephrology</i> , 2013, 45, 537-546.	1.4	7
104	Sotrostatin in Calcineurin Inhibitor-Free Regimen Using Everolimus in De Novo Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2013, 13, 1757-1768.	4.7	34
105	Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. <i>Clinical Transplantation</i> , 2013, 27, 217-226.	1.6	38
106	Transplantation With Kidneys Retrieved From Deceased Donors With Acute Renal Failure. <i>Transplantation</i> , 2013, 95, 611-616.	1.0	61
107	Randomized Trial of Everolimus-Facilitated Calcineurin Inhibitor Minimization Over 24 Months in Renal Transplantation. <i>Transplantation</i> , 2013, 95, 933-942.	1.0	93
108	Influence of deceased donor hemodynamic factors in transplant recipients renal function. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2013, 35, 289-298.	0.9	19

#	ARTICLE	IF	CITATIONS
109	Chronopharmacokinetics of Mycophenolic Acid and Its Glucuronide and Acyl Glucuronide Metabolites in Kidney Transplant Recipients Converted From Cyclosporine to Everolimus. Therapeutic Drug Monitoring, 2012, 34, 652-659.	2.0	8
110	Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transplant International, 2012, 25, 592-602.	1.6	104
111	Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients. Clinical Transplantation, 2010, 24, E116-23.	1.6	11
112	Comparison of the Safety and Efficacy of Cyclosporine Minimization Versus Cyclosporine Elimination in De Novo Renal Allograft Patients Receiving Sirolimus. Transplantation Proceedings, 2010, 42, 1659-1666.	0.6	10
113	Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation. American Journal of Transplantation, 2009, 9, 1876-1885.	4.7	296
114	FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study. Clinical Transplantation, 2009, 23, 589-599.	1.6	20
115	Risk Factors Associated With Graft Loss and Patient Survival After Kidney Transplantation. Transplantation Proceedings, 2009, 41, 3667-3670.	0.6	59
116	Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation. New England Journal of Medicine, 2007, 357, 2562-2575.	27.0	1,603
117	FTY720 Versus Mycophenolate Mofetil in De Novo Renal Transplantation: Six-Month Results of a Double-Blind Study. Transplantation, 2007, 84, 885-892.	1.0	57
118	Tacrolimus Once-Daily Formulation in the Prophylaxis of Transplant Rejection in Renal or Liver Allograft Recipients. Drugs, 2007, 67, 1944-1945.	10.9	4
119	12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transplant International, 2007, 20, 27-36.	1.6	97
120	Immunotherapy for De Novo Renal Transplantation. Drugs, 2006, 66, 1665-1684.	10.9	13
121	Randomized Controlled Trial of FTY720 Versus MMF in De Novo Renal Transplantation. Transplantation, 2006, 82, 1689-1697.	1.0	100
122	Mycophenolic Acid Metabolite Profile in Renal Transplant Patients Receiving Enteric-Coated Mycophenolate Sodium or Mycophenolate Mofetil. Transplantation Proceedings, 2005, 37, 852-855.	0.6	51
123	FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation, 2004, 77, 1826-33.	1.0	66